Dr. Essam Hamza reports

TREATMENT.COM AI PROVIDES LATEST CORPORATE UPDATE

Treatment.com AI Inc. has provided a general corporate update. Treatment.com AI has been working diligently through Q1 and Q2 to ensure continued evolution of its platform (Global Library of Medicine or GLM) and strengthening its pipeline for new business and partnerships. A few key milestones the company has accomplished include the following.

Financial update

On March 13, 2024, the company completed an oversubscribed non-brokered private placement of 6,295,500 special warrants and 975,000 units, issued at 40 cents each, for aggregate gross proceeds of $2,908,200. Each unit consists of one share and one-half of one warrant. Each whole warrant is exercisable for one share at the strike price of 60 cents for a period of two years. On June 21, 2024, the special warrants converted to free-trading units.

The company is also pleased to announce that it is now debt free, having closed a debt settlement transaction with arm's-length creditors in March, 2024, settling an aggregate amount of $461,307.40 in debt, and the recently announced debt settlement transaction on June 27, 2024, whereby the company shall settle an additional $650,000 in debt with arm's-length creditors, which is anticipated to close in the near term.

Dr. Essam Hamza, chief executive officer, states: "We are very appreciative of the strong investor support for our company. This is a critical inflection point for the company; the significant infusion of cash is helping expedite the tremendous commercial opportunity in front of us. We also look forward to the exercising of the warrants, which could bring another over $2-million to the treasury."

New partnerships announced

Treatment.com AI recently announced two new partnerships with aiXplain and Novus Health:

• aiXplain: Enables greater access to Treatment.com AI's proprietary GLM by contributing to aiXplain's ever-growing dynamic artificial intelligence (AI) marketplace. The collaboration also allows aiXplain and Treatment.com AI to work closely on testing and the development of further new mutual joint commercial applications and/or solutions for a global market;
• Novus Health: an acknowledged leader in health navigation supporting over 1.5 million members and their families. Novus Health works with a number of leading North American health insurers and has built a trusted navigation platform that simplifies health care experiences by bringing together everything an individual needs to successfully manage their care journey. Treatment.com AI and Novus Health are looking to collaborate to build out new and differentiated solutions for the health risk assessment and medical second opinion markets.

GLM: further validation of Treatment.com AI's accuracy and effectiveness

While reservations persist in how artificial intelligence can be meaningfully and safely used in health care, Treatment.com AI continues to demonstrate the platform's accuracy and effectiveness. Treatment.com AI recently conducted a trial where a student, using the company's platform, successfully examined 12 test patients under Objective Structured Clinical Examination (OSCE) conditions. The OSCE is a standard clinical exam of diagnostic aptitude at medical and nursing schools in 57 countries globally.

The student, without any prior medical training, entered basic patient information and followed the company's AI-platform-guided prompts to complete individualized assessments. The student then wrote clinical notes summarizing findings and suggested diagnoses. The results were impressive, with the student achieving an accuracy rate of more than 92 per cent (11 of 12 cases) in diagnosing complex conditions, including colon cancer, appendicitis, acute myocardial infarction, diabetes and patellar tendonitis. These results are significantly above results expected from medical students taking the same examinations.

Bolstering the executive, scientific and development team

Richard Atkins: appointed chief operating officer

Mr. Atkins brings to the business a successful career with over 30 years of experience in international sales, partnerships, executive management, and mergers and acquisitions (M&As), highlighted by multiple multimillion-dollar deals working with both major health technology and software corporations.

Mr. Atkins spent his formative career in software and technology, including networking, managed services, data centres and virtualization, omnichannel contact centres, CRM (customer relationship management), enterprise search/data analytics, and cloud-based applications. However, for the past 15 years, he has brought his experience to health care, working across the continuum of care, with a focus on clinical decision support. His experience spans innovative international physical and mental health solutions, including: (i) digital health, healthbots, symptom checkers, telehealth, Alexa voice and social media solutions; (ii) national/provincial teletriage services; (iii) managed PACS/RIS and LIM services in both public/private sectors; (iv) EMR/billing and HL7/FHIR interoperability.

Dr. Jean Challiner: executive adviser

Dr. Challiner is a globally acknowledged expert in clinical decision support. As a doctor with a wealth of clinical experience, Dr. Challiner has helped pioneer specialized technology enabling the delivery of healthcare services since 2002, with a focus on the highest quality of clinical governance.

Dr. Challiner's career began as a general practitioner, moving to accident and emergency with a particular interest in prehospital care. Dr. Challiner received a fellowship in immediate medical care from the Faculty of Pre Hospital Care at the University of Edinburgh, Scotland, in 2001.

For more than 20 years, Dr. Challiner has held executive positions, including medical director or executive director roles with both public bodies (including the U.K. National Health Service (NHS), one of the world's pre-eminent health care systems) and commercial organizations, as well as advisory roles with several early-stage companies. Dr. Challiner's responsibilities have encompassed clinical decision support constructs, governance and clinical safety.

Dr. Challiner's work with organizations globally has helped them transform local and national health care services and patient self assessment in countries as diverse as the United Kingdom, the United States, Australia, New Zealand, Portugal, Scandinavia, Brazil and Ghana.

Given her experience with both national pandemic projects and public health alerts (including the swine flu, Legionnaires disease, the U.K. Polonium incident and the Ebola outbreak in Africa), Dr. Challiner was recently included in the NHS COVID-19 pandemic governance team.

Aligning with Treatment.com AI's vision for health equity, Dr. Challiner is also passionate and committed to the delivery of value-based health care.

Development team

Treatment.com AI has also significantly invested in and expanded its development team through the second quarter of 2024 to help accelerate planned evolution of GLM.

As a result, Treatment.com AI recently announced two new monthly subscription-based SaaS (software-as-a-service) solutions for students, residents and all health care professionals, expected to launch in the second half (H2) of 2024:

• AI Patient: utilizing AI and a library of test cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQs) and OSCE clinical exams;
• AI Doctor in a Pocket: delivers a mobile-friendly AI-powered clinical decision support tool for health care professionals and students when they are in clinics or the hospital.

We seek Safe Harbor.